Compared with placebo, baclofen makes little or no difference to participants who dropped out from treatment, dropped out due to adverse events (side effects), or the number of participants with at least one adverse event. Baclofen probably makes little difference to the number of participants who start drinking again, nor to how much or how often they drink. Baclofen may make little or no difference in the percentage of days people remain alcohol‐free. Baclofen may increase the amount of use measured by number of drinks per drinking days. We found that baclofen increased adverse events like depression, vertigo, somnolence, numbness and muscle rigidity but we did not find significant differences between baclofen and placebo for other ...
BACKGROUND: Baclofen has shown promise in the treatment of alcohol dependence. However, its precise ...
Purpose. We conducted a meta-analysis in order to estimate the efficacy of baclofen on the...
International audienceBackground: Baclofen is a GABA-B receptor agonist currently used in the treatm...
Aim: To carry out a systematic review of the available evidence from health decision makers, patient...
Background and Aims There are a limited number of pharmacotherapies licensed for alcohol use disorde...
A systematic review of the current literature on the efficacy of baclofen, particularly the effect o...
Background: Alcohol withdrawal syndrome (AWS) increases the complexity of inpatient medical care. Ba...
Background Alcohol use disorder (AUD) is one of the most widespread psychiatric disorder leading to...
Recent clinical trials and case-reports indicate that baclofen, a GABAB agonist, may have efficacy f...
Aim: To conduct a double-blind, placebo-controlled randomized clinical trial of baclofen in the trea...
ObjectiveTo evaluate the efficacy and tolerability of baclofen vs. placebo for long-term treatment o...
Aims: The purpose of this study was to examine the long-term effects of baclofen in a large cohort o...
Aims: To explore the effect of baclofen in a dose of 20 mg three times per day, compared with the al...
Both preclinical and clinical research studies have shown the GABA(B) receptor agonist baclofen repr...
AIMS: To explore the effect of baclofen in a dose of 20 mg three times per day, compared with the al...
BACKGROUND: Baclofen has shown promise in the treatment of alcohol dependence. However, its precise ...
Purpose. We conducted a meta-analysis in order to estimate the efficacy of baclofen on the...
International audienceBackground: Baclofen is a GABA-B receptor agonist currently used in the treatm...
Aim: To carry out a systematic review of the available evidence from health decision makers, patient...
Background and Aims There are a limited number of pharmacotherapies licensed for alcohol use disorde...
A systematic review of the current literature on the efficacy of baclofen, particularly the effect o...
Background: Alcohol withdrawal syndrome (AWS) increases the complexity of inpatient medical care. Ba...
Background Alcohol use disorder (AUD) is one of the most widespread psychiatric disorder leading to...
Recent clinical trials and case-reports indicate that baclofen, a GABAB agonist, may have efficacy f...
Aim: To conduct a double-blind, placebo-controlled randomized clinical trial of baclofen in the trea...
ObjectiveTo evaluate the efficacy and tolerability of baclofen vs. placebo for long-term treatment o...
Aims: The purpose of this study was to examine the long-term effects of baclofen in a large cohort o...
Aims: To explore the effect of baclofen in a dose of 20 mg three times per day, compared with the al...
Both preclinical and clinical research studies have shown the GABA(B) receptor agonist baclofen repr...
AIMS: To explore the effect of baclofen in a dose of 20 mg three times per day, compared with the al...
BACKGROUND: Baclofen has shown promise in the treatment of alcohol dependence. However, its precise ...
Purpose. We conducted a meta-analysis in order to estimate the efficacy of baclofen on the...
International audienceBackground: Baclofen is a GABA-B receptor agonist currently used in the treatm...